Mulpleo (Lusutrombopag)

Lusutrombopag, the active ingredient in Mulpleo, is a thrombopoietin receptor agonist presented as a tablet for oral use. It treats thrombocytopenia in patients with chronic liver disease who are undergoing invasive procedures. GNH USA supplies Mulpleo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide.

Mulpleo is a thrombopoietin receptor agonist that acts on platelet production pathways. - Thrombocytopenia in chronic liver disease: helps raise platelet counts before invasive procedures. - Pre‑procedure platelet support: reduces the need for platelet transfusions in at‑risk patients. - Chronic liver disease management: contributes to overall hematologic stability during treatment.

Adverse reactions reported with lusutrombopag are generally mild to moderate.

Common Side Effects: - Headache: mild and transient. - Nausea: occasional, often resolves without intervention. - Fatigue: low‑grade tiredness reported by some patients. - Diarrhea: mild gastrointestinal upset. - Elevated liver enzymes: transient increase in hepatic transaminases.

Serious or Rare Side Effects: - Thromboembolic events: rare but potentially serious clot formation. - Severe hypersensitivity: rash, itching, or swelling requiring medical attention. - Hepatic decompensation: worsening liver function in susceptible individuals. - Severe thrombocytosis: excessively high platelet counts. - Immune‑mediated platelet destruction: rare autoimmune reaction. - Unexplained bleeding: despite platelet rise, rare bleeding episodes may occur.

Mulpleo should be used under careful medical supervision, especially in patients with liver impairment. - Baseline platelet count: obtain before initiating therapy. - Liver function monitoring: assess enzymes periodically. - Concomitant anticoagulants: evaluate bleeding risk when used together. - Pregnancy and lactation: avoid unless benefits outweigh risks. - Renal impairment: adjust use based on clinical judgment. - Store at ambient temperature: keep below 25°C in original packaging, protect from moisture.

Lusutrombopag may interact with several drug classes, requiring attention to dosing and monitoring.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors: may increase lusutrombopag exposure. - Anticoagulants (e.g., warfarin): heightened risk of bleeding.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers: may reduce drug effectiveness. - Other thrombopoietin receptor agonists: additive platelet‑raising effect. - NSAIDs: potential for gastrointestinal irritation. - Herbal supplements affecting liver enzymes: monitor liver function tests.